Everything below concerns modified GRF(1-29). We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
In a nuclear reactor, such a chain reaction is slowed and controlled by a neutron poison, absorbing some of the free neutrons. Such neutron-absorbent materials are often part of reactor control rods (see nuclear reactor physics for a description of this process of reactor control). Other naturally occurring isotopes such as uranium-238 are fissionable, but not fissile, meaning that they only undergo fission when absorbing high energy (fast) neutrons. As little as 15 lb (6.8 kg) of uranium-235 can be used to make an atomic bomb. The nuclear weapon detonated over Hiroshima, Japan, named Little Boy, relied on uranium fission. However, the first nuclear bomb (the Gadget used at Trinity) and the bomb that was detonated over Nagasaki, Japan (Fat Man), were both plutonium bombs. Uranium metal has three allotropic forms:
== Evolution == While the hormone prolactin was discovered in 1928, the prolactin cell itself was not identified and characterized until the 1970s through the use of immunohistochemistry, a technique using antibodies to locate specific hormones within tissues. Prolactin, considered a phylogenetically old signaling molecule, can be traced back 500 million years to lampreys, a jawless vertebrate fish group. The pituitary gland which prolactin cells develop from is itself unique to the vertebrate group. The emergence of the prolactin (PRL) gene in early vertebrate evolution allowed for prolactin cells to gain the regulatory and endocrine functions it maintains within the body. Over time, the role of prolactin within the body diversified as species diversified. In mammals and fish, lactation, mammary gland development, and osmoregulation are the most established functions of prolactin, whereas in birds, prolactin is important for regulating parental behavioral control. The expansion of prolactin cell function over evolutionary history is responsible for the wide distribution of prolactin receptors (PRLRs) within the body, and the diverse physiological effects prolactin hormone has on multiple body systems.
=== Reconstitution of the Indian Forest Service === Singh’s most significant administrative legacy was his successful advocacy for a unified national forestry cadre. He argued that the decentralized provincial structures were fragmented and vulnerable to local political pressures. Under his leadership, the Indian Forest Service was reconstituted and formalized under the All India Services Act, 1951. Notified on September 1, 1966, the IFS became the third All-India Service alongside the Indian Administrative Service (IAS) and the Indian Police Service (IPS). The reform established merit-based recruitment through the Union Public Service Commission (UPSC) and standardized training at the Forest Research Institute.
==== Development of new vaccines ==== It is the important mortality in cages among farmed fish, the debates around DNA injection vaccines, although effective, their safety and their side effects but also societal expectations for cleaner fish and security, lead research on new vaccine vectors. Several initiatives are financed by the European Union to develop a rapid and cost-effective approach to using bacteria in feed to make vaccines, in particular thanks to lactic bacteria whose DNA is modified (Boudinot, 2006). In fact, vaccinating farmed fish by injection is time-consuming and costly, so vaccines can be administered orally or by immersion by being added to feed or directly into water. This allows vaccinating many individuals at the same time while limiting the associated handling and stress. Indeed, many tests are necessary because the antigens of the vaccines must be adapted to each species or not present a certain level of variability or they will not have any effect. For example, tests have been done with two species: Lepeophtheirus salmonis (from which the antigens were collected) and Caligus rogercresseyi (which was vaccinated with the antigens), although the homology between the two species is important, the level of variability made the protection ineffective (Fisheries and Oceans Canada, 2014).
Seeing an opportunity in Napoleon I's historic defeat, Prussia, Sweden and several other German states switched sides, joining Russia, the United Kingdom and others opposing Napoleon. Napoleon vowed that he would create a new army as large as the one he had sent into Russia, and quickly built up his forces in the east from 30,000 to 130,000 and eventually to 400,000. Napoleon inflicted 40,000 casualties on the Allies at Lützen (2 May 1813) and Bautzen (20–21 May 1813). Both battles involved forces of over 250,000, making them some of the largest conflicts of the wars so far. Klemens von Metternich in November 1813 offered Napoleon the Frankfurt proposals. They would allow Napoleon to remain Emperor but France would be reduced to its "natural frontiers" and lose control of most of Italy and Germany and the Netherlands. Napoleon still expected to win the wars, and rejected the terms. By 1814, as the Allies were closing in on Paris, Napoleon I did agree to the Frankfurt proposals, but it was too late and he rejected the new harsher terms proposed by the Allies.
Sources: en.wikipedia.org
The gross (macroscopic) appearance of the brain in Alzheimer's disease is variable. In many cases the cortical sulci are widened and the gyri are shrunken, but the degree of cortical atrophy varies. It can sometimes be difficult to discern, particularly in the very elderly. The areas most affected by atrophy are the medial temporal lobe including the hippocampal formation, the amygdala, the frontal lobe and the parietal lobe; the occipital lobe is relatively unaffected by atrophy. The volume of the ventricles increases in parallel with cortical shrinkage. Studies using MRI and PET have documented reductions in the size of specific brain regions in people with Alzheimer's disease as they progress from mild cognitive impairment to Alzheimer's disease, and in comparison with similar images from healthy older adults. These macroscopic changes in the brain are not specific to Alzheimer's and can occur in other disorders and to some extent in normal aging. At the microscopic level, the defining histopathologic characteristics of Alzheimer's disease are abundant amyloid plaques and neurofibrillary tangles in certain brain regions. Both of these abnormalities are clearly visible by microscopy, and amyloid imaging. In the early stages of disease, tangles are present mainly in the medial temporal lobe and plaques are present mainly in the neocortex, but as the disease progresses the lesions proliferate throughout much of the brain.
Throat culture Anti-DNAse B titre (peaks at 8–12 weeks after infection) Anti-streptolysin O titre (peaks at 3–5 weeks) None of these tests are 100% reliable, particularly when the infection was some months previously. Further testing is directed more towards alternative diagnoses and other manifestations of rheumatic fever:
The adenosine analog NITD008 has been reported to directly inhibit the recombinant RNA-dependent RNA polymerase of the dengue virus by terminating its RNA chain synthesis. This interaction suppresses peak viremia and rise in cytokines and prevents lethality in infected animals, raising the possibility of a new treatment for this flavivirus. The 7-deaza-adenosine analog has been shown to inhibit the replication of the hepatitis C virus. BCX4430 is protective against Ebola and Marburg viruses. Such adenosine analogs are potentially clinically useful since they can be taken orally.
=== Films === In the 1999 film Austin Powers: The Spy Who Shagged Me, it is stated by Number 2 (Robert Wagner) to Dr. Evil (Mike Myers), that while he was frozen, Virtucon invested in the company years prior which has become a major conglomerate. In the 2021 film Ghostbusters: Afterlife, it is stated by Ray Stantz (Dan Aykroyd) that Starbucks had taken over the Ghostbusters' firehouse headquarters at North Moore Street after they went out of business and had turned it into a coffeehouse before Winston Zeddemore (Ernie Hudson) bought it back from them.
== Function == CCK plays important physiological roles both as a neuropeptide in the central nervous system and as a peptide hormone in the gut. It is the most abundant neuropeptide in the central nervous system. CCK has been researched thoroughly for its role in digestion In addition to its role in digestion, CCK is involved in regulating various behavioral phenomena, including satiety, appetite, anxiety, thermoregulation, sexual behavior, memory, and the response to drugs of abuse, particularly within the cortex and limbic regions of the brain.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.